Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy.
T4 monotherapy
combination therapy
hypothyroidism
levothyroxine
liothyronine
pediatrics
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
06
2024
accepted:
22
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Levothyroxine (LT Thyroid function tests (TFTs) were retrospectively extracted from medical charts for patients <19 years old who underwent TT for definitive treatment of Graves' disease (GD) or differentiated thyroid cancer (DTC) between 2010-2021. LT4 dosing was selected to normalize the TSH in GD patients (LT4 replacement) or suppress TSH in DTC patients (LT4 suppression). Pre- and post-surgical TSH, T3 and T4 levels were compared. Of 108 patients on LT A significant number of pediatric patients do not achieve similar T
Identifiants
pubmed: 39205688
doi: 10.3389/fendo.2024.1443394
pmc: PMC11349616
doi:
Substances chimiques
Thyroxine
Q51BO43MG4
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1443394Informations de copyright
Copyright © 2024 Baran, Isaza, Bojarsky, Alzoebie, Song, Halada, Sisko, Gonzales, Mostoufi-Moab and Bauer.
Déclaration de conflit d'intérêts
AB is a consultant for IBSA Pharm and Rare Thyroid Therapeutics/Egetis Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.